Multiple sclerosis (MS) is a chronic inflammatory disorder that is thought to impact about 2.3 million people around the ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

A multiple sclerosis specialist shares insights on quiet progression, and discusses research and treatments for MS activity without relapses.